07.11.16
Headquarters: Tokyo, Japan
www.daiichisankyo.com
Headcount: 18,434
Year Established: 2005
Revenues: $8,770 (+7%)
Net Income: $715 (-75%)
R&D: $1,855 (+9%)
TOP SELLING DRUGS
Daiichi Sankyo unveiled plans during the year to overhaul its U.S. operations, saying the company was transitioning from a maturing primary care product portfolio to a differentiated specialty portfolio including areas such as cardiovascular, pain management and oncology.
To reduce expenses, the company eliminated 1,000 to 1,200 positions across the U.S. commercial function located in Parsippany, NJ, as well as field-based sales and other positions throughout the country. The reorganization does not include U.S.-based R&D functions, which have staff concentrated in Edison, NJ, or its packaging plant in Bethlehem, PA.
The reorganization was driven by the loss of exclusivity on Daiichi Sankyo’s best-selling medication, Olmesartan/Benicar, which loses its patent protection in 2016. Benicar is used in the treatment of hypertension and was responsible for about 27 percent of annual revenue for the company. Last year the medication brought in $2.6 billion. Benicar is prescribed to keep blood vessels from narrowing, which lowers blood pressure and improves blood flow.
Leading up to 2015, Daiichi Sankyo bolstered its pipeline when it gained Phase III acute myeloid leukemia (AML) candidate quizartinib after acquiring Ambit Biosciences in a deal worth $410 million. Ambit is a biopharma company focused on the discovery and development of medicines to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting enzymes behind those diseases. Ambit’s lead drug candidate, quizartinib, is targeted at patients with AML.
In another move, Japan-based Daiichi Sankyo’s U.S. subsidiary merged with its U.S.-based sister company, Asubio Pharmaceuticals, which will be integrated into the Daiichi Sankyo global development organization.
www.daiichisankyo.com
Headcount: 18,434
Year Established: 2005
Revenues: $8,770 (+7%)
Net Income: $715 (-75%)
R&D: $1,855 (+9%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
Olmesartan | hypertension | $2,526 | -3% |
Welchol | cholesterol, type 2 diabetes | $403 | -7% |
Prasugrel | platelet inhibitor | $286 | 29% |
Venofer | iron deficiency | $260 | 0% |
Effient | platelet inhibitor | $173 | 8% |
Daiichi Sankyo unveiled plans during the year to overhaul its U.S. operations, saying the company was transitioning from a maturing primary care product portfolio to a differentiated specialty portfolio including areas such as cardiovascular, pain management and oncology.
To reduce expenses, the company eliminated 1,000 to 1,200 positions across the U.S. commercial function located in Parsippany, NJ, as well as field-based sales and other positions throughout the country. The reorganization does not include U.S.-based R&D functions, which have staff concentrated in Edison, NJ, or its packaging plant in Bethlehem, PA.
The reorganization was driven by the loss of exclusivity on Daiichi Sankyo’s best-selling medication, Olmesartan/Benicar, which loses its patent protection in 2016. Benicar is used in the treatment of hypertension and was responsible for about 27 percent of annual revenue for the company. Last year the medication brought in $2.6 billion. Benicar is prescribed to keep blood vessels from narrowing, which lowers blood pressure and improves blood flow.
Leading up to 2015, Daiichi Sankyo bolstered its pipeline when it gained Phase III acute myeloid leukemia (AML) candidate quizartinib after acquiring Ambit Biosciences in a deal worth $410 million. Ambit is a biopharma company focused on the discovery and development of medicines to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting enzymes behind those diseases. Ambit’s lead drug candidate, quizartinib, is targeted at patients with AML.
In another move, Japan-based Daiichi Sankyo’s U.S. subsidiary merged with its U.S.-based sister company, Asubio Pharmaceuticals, which will be integrated into the Daiichi Sankyo global development organization.